TISIDB

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm
Domain	PF00454 Phosphatidylinositol 3- and 4-kinase PF00792 Phosphoinositide 3-kinase C2 PF02192 PI3-kinase family PF00794 PI3-kinase family PF00613 Phosphoinositide 3-kinase family
Function	Phosphoinositide-3-kinase (PI3K) that phosphorylates PftdIns(4,5)P2 (Phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). PIP3 plays a key role by recruiting PH domain-containing proteins to the membrane, including AKT1 and PDPK1, activating signaling cascades involved in cell growth, survival, proliferation, motility and morphology. Mediates immune responses. Plays a role in B-cell development, proliferation, migration, and function. Required for B-cell receptor (BCR) signaling. Mediates B-cell proliferation response to anti-IgM, anti-CD40 and IL4 stimulation. Promotes cytokine production in response to TLR4 and TLR9. Required for antibody class switch mediated by TLR9. Involved in the antigen presentation function of B-cells. Involved in B-cell chemotaxis in response to CXCL13 and sphingosine 1-phosphate (S1P). Required for proliferation, signaling and cytokine production of naive, effector and memory T-cells. Required for T-cell receptor (TCR) signaling. Mediates TCR signaling events at the immune synapse. Activation by TCR leads to antigen-dependent memory T-cell migration and retention to antigenic tissues. Together with PIK3CG participates in T-cell development. Contributes to T-helper cell expansion and differentiation. Required for T-cell migration mediated by homing receptors SELL/CD62L, CCR7 and S1PR1 and antigen dependent recruitment of T-cells. Together with PIK3CG is involved in natural killer (NK) cell development and migration towards the sites of inflammation. Participates in NK cell receptor activation. Have a role in NK cell maturation and cytokine production. Together with PIK3CG is involved in neutrophil chemotaxis and extravasation. Together with PIK3CG participates in neutrophil respiratory burst. Have important roles in mast-cell development and mast cell mediated allergic response. Involved in stem cell factor (SCF)-mediated proliferation, adhesion and migration. Required for allergen-IgE-induced degranulation and cytokine release. The lipid kinase activity is required for its biological function. Isoform 2 may be involved in stabilizing total RAS levels, resulting in increased ERK phosphorylation and increased PI3K activity.

> Gene Ontology [ TOP ]
Biological Process	GO:0001779 natural killer cell differentiation GO:0002250 adaptive immune response GO:0002263 cell activation involved in immune response GO:0002274 myeloid leukocyte activation GO:0002275 myeloid cell activation involved in immune response GO:0002279 mast cell activation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002443 leukocyte mediated immunity GO:0002444 myeloid leukocyte mediated immunity GO:0002448 mast cell mediated immunity GO:0002521 leukocyte differentiation GO:0002551 mast cell chemotaxis GO:0002573 myeloid leukocyte differentiation GO:0002679 respiratory burst involved in defense response GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0006661 phosphatidylinositol biosynthetic process GO:0006887 exocytosis GO:0007159 leukocyte cell-cell adhesion GO:0008654 phospholipid biosynthetic process GO:0010818 T cell chemotaxis GO:0014065 phosphatidylinositol 3-kinase signaling GO:0014066 regulation of phosphatidylinositol 3-kinase signaling GO:0030098 lymphocyte differentiation GO:0030099 myeloid cell differentiation GO:0030101 natural killer cell activation GO:0030217 T cell differentiation GO:0030258 lipid modification GO:0030335 positive regulation of cell migration GO:0030593 neutrophil chemotaxis GO:0030595 leukocyte chemotaxis GO:0032418 lysosome localization GO:0035747 natural killer cell chemotaxis GO:0035754 B cell chemotaxis GO:0036092 phosphatidylinositol-3-phosphate biosynthetic process GO:0040017 positive regulation of locomotion GO:0042110 T cell activation GO:0042113 B cell activation GO:0043299 leukocyte degranulation GO:0043303 mast cell degranulation GO:0045017 glycerolipid biosynthetic process GO:0045055 regulated exocytosis GO:0045123 cellular extravasation GO:0045576 mast cell activation GO:0045730 respiratory burst GO:0046474 glycerophospholipid biosynthetic process GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0046834 lipid phosphorylation GO:0046854 phosphatidylinositol phosphorylation GO:0048015 phosphatidylinositol-mediated signaling GO:0048017 inositol lipid-mediated signaling GO:0048247 lymphocyte chemotaxis GO:0050851 antigen receptor-mediated signaling pathway GO:0050852 T cell receptor signaling pathway GO:0050853 B cell receptor signaling pathway GO:0050900 leukocyte migration GO:0051272 positive regulation of cellular component movement GO:0051640 organelle localization GO:0051656 establishment of organelle localization GO:0060326 cell chemotaxis GO:0060374 mast cell differentiation GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071593 lymphocyte aggregation GO:0071621 granulocyte chemotaxis GO:0072672 neutrophil extravasation GO:0072676 lymphocyte migration GO:0072678 T cell migration GO:0097529 myeloid leukocyte migration GO:0097530 granulocyte migration GO:0097531 mast cell migration GO:1990266 neutrophil migration GO:2000147 positive regulation of cell motility
Molecular Function	GO:0016303 1-phosphatidylinositol-3-kinase activity GO:0016307 phosphatidylinositol phosphate kinase activity GO:0035004 phosphatidylinositol 3-kinase activity GO:0035005 1-phosphatidylinositol-4-phosphate 3-kinase activity GO:0046934 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0052742 phosphatidylinositol kinase activity GO:0052813 phosphatidylinositol bisphosphate kinase activity
Cellular Component	GO:0005942 phosphatidylinositol 3-kinase complex GO:0019898 extrinsic component of membrane GO:0042629 mast cell granule GO:0061695 transferase complex, transferring phosphorus-containing groups

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04012 ErbB signaling pathway hsa04014 Ras signaling pathway hsa04015 Rap1 signaling pathway hsa04024 cAMP signaling pathway hsa04062 Chemokine signaling pathway hsa04066 HIF-1 signaling pathway hsa04068 FoxO signaling pathway hsa04070 Phosphatidylinositol signaling system hsa04071 Sphingolipid signaling pathway hsa04140 Regulation of autophagy hsa04150 mTOR signaling pathway hsa04151 PI3K-Akt signaling pathway hsa04152 AMPK signaling pathway hsa04210 Apoptosis hsa04360 Axon guidance hsa04370 VEGF signaling pathway hsa04380 Osteoclast differentiation hsa04510 Focal adhesion hsa04550 Signaling pathways regulating pluripotency of stem cells hsa04611 Platelet activation hsa04620 Toll-like receptor signaling pathway hsa04630 Jak-STAT signaling pathway hsa04650 Natural killer cell mediated cytotoxicity hsa04660 T cell receptor signaling pathway hsa04662 B cell receptor signaling pathway hsa04664 Fc epsilon RI signaling pathway hsa04666 Fc gamma R-mediated phagocytosis hsa04668 TNF signaling pathway hsa04670 Leukocyte transendothelial migration hsa04722 Neurotrophin signaling pathway hsa04725 Cholinergic synapse hsa04750 Inflammatory mediator regulation of TRP channels hsa04810 Regulation of actin cytoskeleton hsa04910 Insulin signaling pathway hsa04914 Progesterone-mediated oocyte maturation hsa04915 Estrogen signaling pathway hsa04917 Prolactin signaling pathway hsa04919 Thyroid hormone signaling pathway hsa04960 Aldosterone-regulated sodium reabsorption hsa04973 Carbohydrate digestion and absorption hsa00562 Inositol phosphate metabolism
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers R-HSA-422475: Axon guidance R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-2172127: DAP12 interactions R-HSA-2424491: DAP12 signaling R-HSA-1266738: Developmental Biology R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-186763: Downstream signal transduction R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR) R-HSA-2454202: Fc epsilon receptor (FCERI) signaling R-HSA-392451: G beta R-HSA-397795: G-protein beta R-HSA-180292: GAB1 signalosome R-HSA-388396: GPCR downstream signaling R-HSA-114604: GPVI-mediated activation cascade R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-912526: Interleukin receptor SHC signaling R-HSA-451927: Interleukin-2 signaling R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-187037: NGF signalling via TRKA from the plasma membrane R-HSA-199418: Negative regulation of the PI3K/AKT network R-HSA-1483255: PI Metabolism R-HSA-2219528: PI3K/AKT Signaling in Cancer R-HSA-198203: PI3K/AKT activation R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling R-HSA-1257604: PIP3 activates AKT signaling R-HSA-1483257: Phospholipid metabolism R-HSA-76002: Platelet activation, signaling and aggregation R-HSA-8853659: RET signaling R-HSA-912631: Regulation of signaling by CBL R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization R-HSA-162582: Signal Transduction R-HSA-177929: Signaling by EGFR R-HSA-372790: Signaling by GPCR R-HSA-449147: Signaling by Interleukins R-HSA-186797: Signaling by PDGF R-HSA-1433557: Signaling by SCF-KIT R-HSA-983705: Signaling by the B Cell Receptor (BCR) R-HSA-166520: Signalling by NGF R-HSA-1660499: Synthesis of PIPs at the plasma membrane

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04012 ErbB signaling pathway
hsa04014 Ras signaling pathway
hsa04015 Rap1 signaling pathway
hsa04024 cAMP signaling pathway
hsa04062 Chemokine signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04068 FoxO signaling pathway
hsa04070 Phosphatidylinositol signaling system
hsa04071 Sphingolipid signaling pathway
hsa04140 Regulation of autophagy
hsa04150 mTOR signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04152 AMPK signaling pathway
hsa04210 Apoptosis
hsa04360 Axon guidance
hsa04370 VEGF signaling pathway
hsa04380 Osteoclast differentiation
hsa04510 Focal adhesion
hsa04550 Signaling pathways regulating pluripotency of stem cells
hsa04611 Platelet activation
hsa04620 Toll-like receptor signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04650 Natural killer cell mediated cytotoxicity
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04664 Fc epsilon RI signaling pathway
hsa04666 Fc gamma R-mediated phagocytosis
hsa04668 TNF signaling pathway
hsa04670 Leukocyte transendothelial migration
hsa04722 Neurotrophin signaling pathway
hsa04725 Cholinergic synapse
hsa04750 Inflammatory mediator regulation of TRP channels
hsa04810 Regulation of actin cytoskeleton
hsa04910 Insulin signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
hsa04915 Estrogen signaling pathway
hsa04917 Prolactin signaling pathway
hsa04919 Thyroid hormone signaling pathway
hsa04960 Aldosterone-regulated sodium reabsorption
hsa04973 Carbohydrate digestion and absorption
hsa00562 Inositol phosphate metabolism

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-983695: Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
R-HSA-422475: Axon guidance
R-HSA-2219530: Constitutive Signaling by Aberrant PI3K in Cancer
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-2172127: DAP12 interactions
R-HSA-2424491: DAP12 signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-186763: Downstream signal transduction
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-392451: G beta
R-HSA-397795: G-protein beta
R-HSA-180292: GAB1 signalosome
R-HSA-388396: GPCR downstream signaling
R-HSA-114604: GPVI-mediated activation cascade
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-912526: Interleukin receptor SHC signaling
R-HSA-451927: Interleukin-2 signaling
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-199418: Negative regulation of the PI3K/AKT network
R-HSA-1483255: PI Metabolism
R-HSA-2219528: PI3K/AKT Signaling in Cancer
R-HSA-198203: PI3K/AKT activation
R-HSA-6811558: PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
R-HSA-1257604: PIP3 activates AKT signaling
R-HSA-1483257: Phospholipid metabolism
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-8853659: RET signaling
R-HSA-912631: Regulation of signaling by CBL
R-HSA-2730905: Role of LAT2/NTAL/LAB on calcium mobilization
R-HSA-162582: Signal Transduction
R-HSA-177929: Signaling by EGFR
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins
R-HSA-186797: Signaling by PDGF
R-HSA-1433557: Signaling by SCF-KIT
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-1660499: Synthesis of PIPs at the plasma membrane

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PIK3CD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between PIK3CD and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27656909	Melanoma; Breast Carcinoma	Inhibit immunity; immunotherapy target	The combinations of nanoscale MEK- and PI3K-targeting supramolecular therapeutics with checkpoint PDL1 and PD1 inhibitors exert enhanced antitumor outcome in melanoma and breast cancers in vivo, respectively.
22364281	Acute Lymphoblastic Leukemia; Lymphoma	Inhibit immunity (T cell function); immunotherapy target	Genetic and pharmacological experiments have shown that PI3K activation regulates many steps in the development, activation and differentiation of both B- and T-cells. An exciting discovery is that a selective inhibitor of the p110δ catalytic isoform of PI3K, CAL-101, achieves impressive clinical efficacy in certain B-cell malignancies. A model is emerging in which p110δ inhibition disrupts signals from the lymphoid microenvironment, leading to release of leukaemia and lymphoma cells from their protective niche.
24919154	leukaemia	Inhibit immunity (T cell function); immunotherapy target	We demonstrate that p110δ inactivation in regulatory T cells unleashes CD8(+) cytotoxic T cells and induces tumour regression.
21441454	Melanoma	Inhibit immunity	Interaction of LAG-3 with MHC II expressed on melanoma cells upregulates both MAPK/Erk and PI3K/Akt pathways, albeit with different kinetics. Inhibition studies using specific inhibitors of both pathways provided evidence of their involvement in the LAG-3-induced protection from apoptosis.
28108509	Lung Carcinoma	Inhibit immunity; Resistant to immunotherapy	Conversely, PI3Kδ was functionally critical in Treg, acting there to control T-cell receptor signaling, cell proliferation, and survival. Notably, in a murine model of lung cancer, coadministration of a PI3Kδ-specific inhibitor with a tumor-specific vaccine decreased numbers of suppressive Treg and increased numbers of vaccine-induced CD8 T cells within the tumor microenvironment, eliciting potent antitumor efficacy.
25080445	Melanoma; Colon Carcinoma; Lymphoma	Inhibit immunity	Furthermore, these PI3K-Akt inhibitors led to a significant therapeutic antitumor effect, which was shown to be Treg dependent. Here, we report the use of PI3K-Akt pathway inhibitors as potent agents for the selective depletion of suppressive Tregs. We found that PI3K-Akt pathway inhibitors selectively inhibit Tregs with minimal effect on conventional T cells
16849475	lymphoma	Promote immunity	This activity evidently derives from a 25-kDa fragment of beta-glucan released by macrophage processing of the parent polysaccharide. This fragment, but not parent beta-glucan, binds to neutrophil CR3, induces CBRM 1/5 neoepitope expression, and elicits CR3-dependent cytotoxicity. Thus, beta-glucan enhances tumor killing through a cascade of events, including in vivo macrophage cleavage of the polysaccharide, dual CR3 ligation, and CR3-Syk-PI3K signaling. These results are important inasmuch as beta-glucan, an agent without evident toxicity, may be used to amplify tumor cell killing and may open new opportunities in the immunotherapy of cancer.

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PIK3CD in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PIK3CD in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.172	0.683
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.464	0.424
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.772	0.574
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.245	0.587
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.084	0.964
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.67	0.797
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.311	0.45
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.573	0.723
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.017	0.992
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.605	0.139
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.254	0.467
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.174	0.257

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PIK3CD in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	7.1	-7.1	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	4.1	-4.1	0.561
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	6.2	4.9	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	20	11.1	8.9	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	0	9.1	0.458
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	16.7	0	16.7	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PIK3CD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PIK3CD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PIK3CD. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PIK3CD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PIK3CD expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PIK3CD and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PIK3CD
Name	phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta
Aliases	p110D; phosphatidylinositol 3-kinase, catalytic, delta polypeptide; phosphoinositide-3-kinase C; phosphoinos ......
Chromosomal Location	1p36.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PIK3CD collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting PIK3CD.

ID	Name	Drug Type	Targets	#Targets
DB00201	Caffeine	Small Molecule	ADORA1, ADORA2A, ATM, ITPR1, ITPR2, ITPR3, PDE10A, PDE11A, PDE1A, ......	33
DB05241	XL765	Small Molecule	MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG	5
DB06831	2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE	Small Molecule	PIK3CD, PIK3CG	2
DB12483	Copanlisib	Small Molecule	PIK3CA, PIK3CD	2

Browse PIK3CD